Spots Global Cancer Trial Database for SU5416 in Treating Patients With Advanced or Recurrent Cancer of the Head and Neck

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: SU5416 in Treating Patients With Advanced or Recurrent Cancer of the Head and Neck

Official Title: A Phase II Trial of SU5416 (NSC #696819) in Patients With Advanced or Recurrent Squamous Cell Carcinoma of the Head and Neck

Study ID: NCT00006361

Conditions

Carcinoma of Unknown Primary

Head and Neck Cancer

Non-melanomatous Skin Cancer

Interventions

semaxanib

Study Description

Brief Summary: RATIONALE: SU5416 may stop the growth of cancer cells by stopping blood flow to the tumor. PURPOSE: Phase II trial to study the effectiveness of SU5416 in treating patients who have advanced or recurrent cancer of the head and neck.

Detailed Description: OBJECTIVES: * Determine the effect of SU5416 on survival and tumor response in patients with advanced or recurrent squamous cell carcinoma of the head and neck. * Determine the safety and toxicity of SU5416 in these patients. OUTLINE: Patients receive SU5416 IV over 1 hour twice weekly. Treatment continues in the absence of disease progression or unacceptable toxicity. Patients are followed for 1 year. PROJECTED ACCRUAL: A total of 35 patients will be accrued for this study within 1.4 years.